



Outsourcing In Clinical Trials East Coast 2023

King of Prussia, PA, USA

23rd – 24th May 2023 www.arena-international.com/event/octeastcoast/



Discover effective strategies for outsourcing clinical trial operations to ensure trials run smoothly and within budget.

Join us for a two-day event filled with case studies, panel discussion and face to face networking opportunities around clinical operations, technology and innovation, and data management.

2023 Speakers

Experience high-level discussions and talks from industry leaders

2023 Speakers Include...

Craig Lipset, Advisor and Founder, Clinical Innovation Partners

Rosalie Filling, Vice President, Clinical Operations & Biometrics, Endo Pharmaceuticals

Peter O'Neill, Sr. Director, Clinical Operations, Incyte

John Gregg, Chairman and CEO at BalinBac Therapeutics, Inc.

Dr. Harsha Karur Rajasimha, President, IndoUSRare

Jill McNair, Chief Growth Officer, CISCRP

Narayan Lebaka, Senior Director of clinical data management, Inspirna (formerly known as Rgenix)
Rick O'Hara, Director of R&D Business Operations, Endo Pharmaceuticals
Anthony Fuller, Global Head of Sourcing, Mitsubishi Tanabe Pharma Development America
Ram Raju, Senior Vice President and Community Health Investment Officer, Northwell Health
Frank Leu, CEO, BioPharMatrix

Carrie Lewis, Executive Director, Clinical Program Optimization, Endo Pharmaceuticals
Adam Barrows, Executive Director - Solid Tumour TA Head, Bristol Myers Squibb
Kathleen Cohen, Head of Clinical Operations, Marinus Pharma
Ella Balasa, Patient Advocate, speaker, published writer, and health engagement consultant
Kelly Ragins, Global Head of Portfolio Delivery Office, Novartis
Anka G. Ehrhardt, Director, Cell-Based Sciences, AR&D, Merck
Venkat Sethuraman, Head of Global Biometrics and Data Sciences, Bristol Myers Squibb

Venkat Sethuraman, Head of Global Biometrics and Data Sciences, Bristol Myers Squibb

Adam Kinsey, Associate Vice President, Global Clinical Trial Operations (GCTO), Head of GCTO North America,

Merck

Susan Maloney, Former Associate Vice President, Head Clinical Operations, PhaseBio

Linda Blount, President, Rare Disease Diversity Coalition Jenifer Waldrop, Executive Director, Rare Disease Diversity Coalition

Evan Tzanis, Chief Operating Officer and Executive Vice President, Head of R&D, Neuraptive Therapeutics

Dominique Duchesne, Director, Clinical Operations Lead, Bristol Myers Squibb

Kevin Shipe, Director, Head of Strategic Sourcing and Study Start-up, INOVIO Pharmaceuticals

Jen Horonjeff, CEO, Savvy Cooperative

Jenny Wakefield, Senior Director- Quality Development Operations, Incyte
Sherin Abdel-Meguid, President, Shifa Biomedical Corporation
Candice Estes, Clinical Trial Manager, Clinical Operations, Incyte
Hassan Kadhim, Senior Director, Head of Clinical Trial Business Capabilities, Bristol Myers Squibb
Terry Katz, Sr Director, Biostatistics and Data Management Planning and Functional Excellence, Daiichi
Sankyo, Inc.

Travis Caudill, Vice President Feasibility, Site Identification & Clinical Informatics. Feasibility & Site Identification Integration Workstream Lead, ICON

Sverre Bengtsson, Co-Founder, Senior Vice President Strategic Relations, Viedoc
Keith Kennedy, Principal and Team Lead, Patient Cloud, Medidata
Ellen Weiss, Vice President, In-Home Solutions, Decentralized Clinical Trials, PCM Trials
Dr. YuFeng Li, Executive Director, Clinical Development, Qilu Pharmaceuticals
Alison Bedenkop, Senior Director, Patient Recruitment and Retention, Worldwide Clinical Trials



7:30	Registration and refreshments
8:20	Chairperson's opening remarks: Peter O'Neill, Sr. Director, Clinical Operations, Incyte



Keynote We Are All At-Risk of Being Obsolete: Earning Our Place in the Future of Clinical Research Clinical research is a crucial part of delivering a healthy society, and no stakeholder involved in the process today has a "right" to be here tomorrow. There are futures where every entity in research is at risk of being made obsolete. How can we best avoid complacence and ensure we are all earning the right to be at this table?
Craig Lipset, Advisor and Founder, Clinical Innovation Partners
Session Reserved for NOVOTECH
Artificial Intelligence & the future of clinical trials: the potential of AI to help with study planning
 Identify and assess the possibilities for AI in your clinical trial Understanding the technologies behind AI such as machine learning, deep learning, neural networks, and algorithms
 Social and ethical implications of Artificial Intelligence A contextual understanding of AI, its history, and evolution, helping you to make relevant
 predictions for its future trajectory. Looking at how to successfully implement AI into your clinical trial
Venkat Sethuraman, Head of Global Biometrics and Data Sciences, Bristol Myers Squibb
Optimize Your Trial Execution with the Strategic Use of an Experienced Technology Solutions Team It takes more than reading a protocol to design and implement technology for a successful clinical trial. It takes years of knowledge and experience to fully understand the risks and provide meaningful insights into best practices that ensure all stakeholders achieve their goals. Before and during a clinical trial, planning decisions across many complex processes is required.
Areas of discussion will include how an expert and experienced team can set up your organization for success in all phases, including.
• study design
• recommendations
 blinding concerns mid-study changes
supply management
Kevin Collier, VP, Medidata



Sales Enquiry
Ben Lloyd-Davies
Head of Sponsorship Sales
T: +44 (0)207 9472755
E: BenLloyd-Davies@arenainternational.com

Speaker Enquiry
Maya Hudson
Senior Conference Producer
E: Maya.Hudson@arenainternational.com

Marketing Enquiry
Haida Amirzadah
Senior Marketing Manager
E: Haida.Amirzadah@arenainternational.com

10:30 Mornin	ng Refreshments & Networking	
O	UTSOURCING & CLINICAL OPERATIONS	CLINICAL INNOVATION & TECHNOLOGY
	air: Rosalie Filling, Vice President, Clinical ations & Biometrics, Endo Pharmaceuticals	Chair: Peter O'Neill, Sr. Director, Clinical Operations, Incyte
Abstract patient pillars of patient recognineeds of relation engage.	te the therapeutic development process at: Gain a comprehensive understanding of a si journey to advocacy highlighting important of successful patient engagement directly from a advocate's experiences. Understanding and zing the barriers, burdens, knowledge gaps, and if patients allows for strengthened patient aships and optimizes long term gains in patient ment strategies Treating the patient as more than a consumer builds the foundation for patient relationships Recognizing and mitigating the barriers patient trial participation and retention Understanding the value of incorporating the patient voice from the inception and design of research and trials through drug development Improving health literacy and ensuring transparency builds trust Maintaining patient relationships through a feedback loop of dissemination of trial results and cocreation in design strengthens future research asa, Patient Advocate, speaker, published writer, alth engagement consultant	Data Management in Oncology; the importance of using suitable technology in your clinical trial, leading to a manageable data structure • Challenges: How we collect data – number of data forms and adverse effects in oncology • Using the right technology • Understanding the importance of data • Looking at how to manage your data structure Narayan Lebaka, Senior Director of clinical data management, Inspirna (formerly known as Rgenix)

The Last Millimeter is Everything: Essential Guide for Home Visits

- Home visits have evolved since their inception in 2003
- Services possible in 2023 an overview of what is possible today
- Sourcing the right professionals for visits is essential to success

Ellen Weiss, Vice President, In-Home Solutions, Decentralized Clinical Trials, **PCM Trials**

11:30

12:00

Advancements in AI: turning big data into actionable intel for optimal site identification

Despite advancing technologies, trials still struggle to meet patient enrolment goals. Slow enrollment directly impacts schedule and budget, with each day of delay carrying cripplingly high costs. Successful, timely patient recruitment is directly linked to effective site selection. Conversely, selecting the wrong site can negatively impact recruitment or result in total failure to enroll patients. Join us to learn how advancements in AI can help the pharma industry identify the best sites for their clinical trials through the harnessing of big data. Topics include:

- Transitioning from data overload to data driven decision-making
- The role of Artificial Intelligence in optimizing site identification and selection
- Expected and unexpected downstream benefits of an Al-enabled site selection strategy

Travis Caudill, Vice President Feasibility, Site Identification & Clinical Informatics
Feasibility & Site Identification Integration Workstream
Lead, ICON

Panel: Reversing the Conversation: What the clinical trial industry really wants from its service providers

We've all had to sit through several pitches from vendor companies telling us what they can do for us, but now it's time to reverse the conversation! Hear from the trial industry as they discuss the services, they would like to see from their solution providers, including:

What they like to see in an outsourced partner organization

- What they would like a partner to know about them / how they work
- What things do they need a partner to do and what they don't need!
- What things can be best done in house?

Moderator: Rosalie Filling, Vice President, Clinical Operations & Biometrics, **Endo Pharmaceuticals**

Panellists:

Kathleen Cohen, Head of Clinical Operations, **Marinus Pharma**

Adam Kinsey, Associate Vice President, Global Clinical Trial Operations (GCTO), Head of GCTO North America, **Merck**

FIRESIDE CHAT

Are We Committed to "Not Going Back"?

The rapid introduction of new approaches to sustain clinical trials during the COVID-19 pandemic drove substantial early enthusiasm that there was "no going back"



But with the convergence of the end of the pandemic along with a challenging economic environment, can we sustain this promise? How do we mitigate the risk of sliding backward and losing the positive changes introduced during the last two years?

- Discuss the factors bringing new challenges to the adoption of innovative approaches in clinical trials
- Explore how some organizations may be "over the crest" in change and adoption while others may "slide back"
- Consider strategies to sustain forward momentum and progress despite new organizational challenges

Craig Lipset, Advisor and Founder, Clinical Innovation
Partners

Hassan Kadhim, Senior Director, Head of Clinical Trial Business Capabilities, **Bristol Myers Squibb**



Sales Enquiry
Ben Lloyd-Davies
Head of Sponsorship Sales
T: +44 (0)207 9472755
E: BenLloyd-Davies@arenainternational.com

Speaker Enquiry
Maya Hudson
Senior Conference Producer
E: Maya.Hudson@arenainternational.com

Marketing Enquiry
Haida Amirzadah
Senior Marketing Manager
E: Haida.Amirzadah@arenainternational.com

	Novotech	
	•	
	100	
	Clinical Trial Liaisons Support of Psychedelic	
	Clinical Trials	
		Session Reserved for YPrime
	Psychedelic-assisted therapy has shown	
	potential in the treatment of severe mood	Donna M. Mongiello, RN, BSN, Senior VP, Strategic
	and anxiety disorders, including major	Solutions, YPrime
	depressive disorder (MDD) and post-	
	traumatic stress disorder (PTSD)	Joseph Im - Director, Digital Health Technologies
	Worldwide is a leader in psychedelics and	Operations
	understands the importance of selecting	
12:45	sites that have the appropriate support	
	services as well as specialized training	THE A SALES OF THE SALES
	Worldwide Clinical Trial Liaisons (CTL)	
	provide support to sites as they navigate	
	psychedelic clinical trials, helping sites	
	integrate psychedelic clinical studies into	
	their practice and manage expectations	
	Alison Bedenkop, Senior Director, Patient	
	Recruitment and Retention, Worldwide Clinical	
	Trials	
1:15	Lunch and networking	

Protecting our planet: Leveraging study participants' Real-World Data to enable Sustainable drug development researchers to confirm the representativeness of the **baseline;** A patient enrols in a trial, is administered test drug, and has an outcome. Post-treatment results are compared to pre-treatment to claim a change from Understanding the baseline. That is the classic method to establish a drug environmental and effect, whether it's a positive treatment outcome or an social impacts of clinical trials adverse effect. But, this absolute dependence on the single 2:15 Collaborating with supplier ecosystems to drive baseline measurement may be unsubstantiated. sustainability goals Looking at the reliability of baseline values Sustainability by design: innovation and Leveraging real world data for that participant changing behaviours from their Electronic Medical Record Terry Katz, Sr Director, Biostatistics and Data Management Anthony Fuller, Global Head of Sourcing, Mitsubishi Planning and Functional Excellence, Dailchi Sankyo, Inc. Tanabe Pharma Development America 15 minutes Tech Showcase Reserved for Session Sponsor Running Up That Hill: Accelerate Cycle Times & **Reach Patients Faster with elluminate** Operational oversight within outsourced models has become increasingly complex for teams who are tasked with managing trials amid a rapidly changing landscape of partners, technologies, and global regulations. Data proliferation along with dwindling resources has made it a top priority for clinical development teams to look to technology to improve Session Reserved for Paraxel cycle times and the overall experiences of data 2:45 managers, medical monitors, and clinical operations leaders. This presentation will highlight how the elluminate Clinical Data Cloud and Biometrics Services can reshape your data architecture by automating data flows to keep up with the pace of data evolution and speed time to insights. Learn how elluminate and eClinical's Biometrics Services deliver: Operational insights across numerous data sources that provides definitive answers and analytics on enrollment, protocol compliance



and safety

		 Improved study oversight with a holistic view of risk across all data sources 50 out-of-the-box visualizations to support supports cross-study analysis for deeper insights with self-service access to clinical and operational analytics Increased productivity across data management, medical monitoring, clinical operations, clinical programming and statistical analysis roles Dawn Kaminski, Vice President, BD Operations, eClinical Solutions
3:15	 Encouraging public health literacy, patient education and engagement; informing and empowering patients and the public as partners in clinical research. Focusing on nurturing our established relationships, building new ones, and on identifying and developing new opportunities. Discussing how to serve patient communities and clinical research stakeholders throughout the world with the highest quality educational and advocacy services 	Exploration of AI training, accuracy, and the precision of outputs in the validation of clinical data Rakesh Maniar, Head of eClinical Technologies, Global Data Management & Standards, Merck & Co
3:45	Afternoon refreshments and networking	

How CRO's can help sponsors be the sponsor of choice, Featured New Technology Presentation: Administration a partnership with CRO's population of sites and of Respiratory Therapeutics with a Device and Fixed Dose conducting clinical trials **Drug Combination Using Portable Medical Vaporizers** First usage of Portable Therapeutic Vaporizers as a Removing the bias for sites to engage with CROs in the same way as sponsors new delivery modality for prescription drugs The ability to leverage a CRO's global reach for arising out of technologies originally developed as clinical trial site footprint electronic nicotine delivery systems (ENDS) Advantages in safety and efficacy of delivering Adam Barrows, Executive Director - Solid Tumour TA respiratory drug regimens directly to sinus, throat Head, Bristol Myers Squibb and lung tissue in gas vapor form 4:15 Likely regulation of a new therapeutic delivery modality Clinical trial challenges for therapeutic vape device and drug systems John Gregg, Chairman and CEO at BalinBac Therapeutics, Hybrid trials using DCT technology and processes; focus on patients and the sites Session Reserved for TrialCard Highlighting the complexity that Hybrid/DCT brings whilst moving away from the common brick-and-mortar sites Discussing the rise in regulator concerns in areas such as investigator oversight, and participant's safety when face to face contact is limited How we tend to focus too much on 4:45 technology when it's actually the processes for the patients and the sites that matter even more Major points to consider in designing hybrid/DCT trials; building blocks and practical examples to best prepare you to meet the needs of regulators whilst keeping the patient and sites front of mind **Sverre Bengtsson**, Co-Founder, Senior Vice President Strategic Relations, **Viedoc**



PANEL: Addressing the issues with Decentralised Clinical Trials and how we may work collaboratively to overcome them; addressing the pitfalls & challenges

There are varied viewpoints on the success of DCT's, we are therefore using this panel as a platform to discuss issues raised within processes

- Are timelines actually increasing? Taking into consideration site staff turnover and knowledge base
- It is said DCT's will enhance patient recruitment, is this the truth in practice? Looking into patient's ability to par-take and keep to trial timelines considering factors beyond our control
- Site Perspective; their involvement with sponsors and the differences with their involvement of the trial

5:15

Moderator: Peter O'Neill, Senior Director, Clinical Operations, Incyte

Panelists:

Anka G. Ehrhardt, Director, Cell-Based Sciences, AR&D, Merck

Dominique Duchesne, Former Director, Clinical Operations Lead, Bristol Myers Squibb

Susan Maloney, Former Associate Vice President, Head Clinical Operations, PhaseBio

Keith Kennedy, Principal and Team Lead, Patient Cloud, Medidata

Candice Estes, Clinical Trial Manager, Clinical Operations, Incyte

5:45

Chairperson's closing remarks followed by Drinks Reception

END OF DAY 1 AND NETWORKING DRINKS



Outsourcing In Clinical Trials East Coast 2023

King of Prussia, PA, USA

23rd - 24th May 2023

DAY TWO – WEDNESDAY 24TH MAY 2023

8:15	Registration and refreshments	
	Outsourcing & Clinical Operations Chair: Rosalie Filling, Vice President, Clinical Operations & Biometrics, Endo Pharmaceuticals	Clinical Innovation & Technology Chair: Peter O'Neill, Sr. Director, Clinical Operations, Incyte
08:45	 What does it really take to achieve global IDEA in clinical trials? Inclusion, Diversity, Equity, and Access Major barriers to achieving IDEA for sponsors and investigator teams Recent regulatory guidelines Strategies for achieving IDEA in clinical trials Dr. Harsha Karur Rajasimha, President, IndoUSRare 	 Digital and telehealth; remote monitoring in clinical trials Integrating apps and wearables into your clinical study: what additional benefits can this bring? Combining remote monitoring with risk-based monitoring to deliver a successful decentralised trial How consumer-wearables can provide enhanced access to clinical trials Compiling data from wearables to contribute toward clinical trials Overcoming common issues around using data collected remotely Jen Horonjeff, CEO, Savvy Cooperative
09:15	Session Reserved for Clario	Session Reserved for Saama Technologies
09:45	Interactive Session The Elephant in the room – what is holding you back from developing key relationships when managing your trials? Are you in your own way? How do you relate and interact with: Your Study Team Your Vendors Your Manager Yourself	Blockchain – Exploring the Implications for the Future In this session Frank Leu, CEO at BioPharMatrix explores where he sees Blockchain going in the future, its implications and whether we should all be investing in it. What is blockchain? How can it be adapted in the Clinical Trial? Why do we need to reach a consensus platform as soon as possible? Who gets to decide this, will it be FDA or the Pharma industry? What would be its cost impact on drug development?



	Are you willing to face others' perceptions of you?	Why does the C-suite need to engage in blockchain use immediately?
	This will be a brief presentation followed by an Open discussion on some barriers to communication that Clinical Operations professional experience.	Frank Leu, CEO, BioPharMatrix
	Jenny Wakefield, Senior Director- Quality Development Operations, Incyte	
10:30	Morning refreshments and networking	
	OUTSOURCING & CLINICAL OPERATIONS	CLINICAL INNOVATION & TECHNOLOGY
	Chair: Rosalie Filling, Vice President, Clinical Operations & Biometrics, Endo Pharmaceuticals	Chair: William Newton, Senior Healthcare Reporter, GlobalData Healthcare
	Population Health & Diversity in Clinical Trials	Fireside Chat
	Highlighting the importance of inclusion	Leveraging global trial footprint to accelerate clinical development
11:00	 Focusing on the opportunities within Decentralised Clinical Trials to encourage enhanced enrolment of minority and diverse populations into research Understanding why we struggle to recruit a varied patient population; how improving our recruitment can improve our study results Looking into the best step forward Ram Raju, Senior Vice President and Community Health Investment Officer, Northwell Health 	Clinical trial conduct is facing multiple challenges from budget pressure, patient recruitment difficulties, to regulatory uncertainties. At the beginning of each development program, companies need to plan for global trial capabilities by utilizing multiple geographic locations for clinical trials to accelerate the development process. This approach allows for larger and more diverse patient populations to be enrolled, leading to faster completion of trials and ultimately getting treatments to market faster. A global trial footprint also enables the collection of data in different regions and across different populations, providing valuable insights into the efficacy and safety of treatments. By leveraging a global trial footprint, biotech and pharmaceutical companies can overcome barriers to clinical development and bring life-saving treatments to patients more quickly. Moderator: William Newton.
		Moderator: William Newton, Senior Healthcare Reporter, GlobalData Healthcare Speaker: Dr. YuFeng Li, Executive Director, Clinical Development, Qilu Pharmaceuticals
11:30	Session Reserved for WCG	Leveraging predictive analytics to improve patient retention, data quality, and enrollment outcomes in clinical trials Clinical trial data complexity has tripled in the past decade leading to fragmented data, insights, and stakeholder



collaboration. These data complexities pose significant inefficiencies in the research and drug development process and are exacerbated as clinical operations teams become leaner and cost-constrained. In this presentation, you will gain insight to real world case studies that use Lokavant to radically improve clinical trial outcomes, as well as overall successes for leaner study Rohit Nambisan, CEO & Co-Founder, Lokavant PANEL DISCUSSION **PANEL DISCUSSION** Focusing on today's Innovation & Technological What are the different outsourcing relationships and how **Advancements** do you manage them? Are we making the most of Technology & What are the categories and the driving needs for Innovation in the Clinical Trial space? How are these tools being utilised? How has this changed over the years? What's next? Key strategies that sponsor companies have - how Moderator: William Newton, Senior Healthcare Reporter, has this changed? GlobalData Healthcare Did the pandemic effect these strategies? 12:00 Panelists: Moderator: Rosalie Filling, Vice President, Clinical Peter O'Neill, Sr. Director, Clinical Operations, Incyte Operations & Biometrics, Endo Pharmaceuticals Frank Leu, CEO, BioPharMatrix Panelists: Rakesh Maniar, Head of eClinical Technologies, Global **Kevin Shipe, Director,** Head of Strategic Sourcing and Study Data Management & Standards, Merck & Co Start-up, INOVIO Pharmaceuticals Adam Barrows, Executive Director - Solid Tumour TA Head, **Bristol Myers Squibb** Sherin Abdel-Meguid, President, Shifa Biomedical Corporation 12:45 **Lunch and Networking** Collaborating across Functions to Improve the Forecasting, Budgeting, and Accruals Process This fireside chat will focus on the accrual/forecasting process for Clinical trial budgets. Specifically, the processes for working with vendors to obtain current accruals and forecasts. We will also discuss coordination with the internal functions at the Sponsor to ascertain the most accurate and current timelines, enrollment 1:45 rates, screen failure and drop out rates. Aligning all expectations with both the operations teams as well as Finance and Senior Management.



Sales Enquiry **Ben Lloyd-Davies**Head of Sponsorship Sales
T: +44 (0)207 9472755
E: BenLloyd-Davies@arena-international.com

Carrie Lewis, Executive Director, Clinical Program Optimization, Endo Pharmaceuticals

Rick O'Hara, Director of R&D Business Operations, Endo Pharmaceuticals

Speaker Enquiry
Maya Hudson
Senior Conference Producer
E: Maya.Hudson@arenainternational.com

Marketing Enquiry
Haida Amirzadah
Senior Marketing Manager
E: Haida.Amirzadah@arenainternational.com

PANEL Diversity & Inclusion in Clinical Trials Increasing diversity in clinical trials; overcoming critical barriers Focusing on the application of diverse populations Action for increasing diversity **Regulatory Updates** 2:15 Moderator: Linda Blount, President, Rare Disease Diversity Coalition Panelists: Jenifer Waldrop, Executive Director, Rare Disease Diversity Coalition Dr. Harsha Karur Rajasimha, President, IndoUSRare Jen Horonjeff, CEO, Savvy Cooperative Ram Raju, Senior Vice President and Community Health Investment Officer, Northwell Health 3:00 Afternoon refreshments and Apple prize draw **ROUNDTABLE SESSIONS** 3:30 During the roundtable discussion session, the conference hall will be divided into zones. Delegates can choose which zone they would like to join. Each zone will be led by a table moderator and will focus on a different <mark>challenge within the industry. After 30 minutes, delegates will have the opportunity to swap and choo</mark>se a different table, and each roundtable will run twice. Roundtable 1 Strategies for Country and Site Selection Kelly Ragins, Global Head of Portfolio Delivery Office, Novartis Roundtable 2 Implementing effective vendor management tools and communication strategies to avoid the failure of Kathleen Cohen, Head of Clinical Operations, Marinus Pharma Roundtable 3 Top Tips in Effective Budget Management, Forecasting and Contracting: Ensuring Your Resources Are **Allocated Correctly** Kevin Shipe, Director, Head of Strategic Sourcing and Study Start-up, INOVIO Pharmaceuticals Roundtable 4 Decentralised Clinical Trials; a discussion on transforming clinical trial development Candice Estes, Clinical Trial Manager, Clinical Operations, Incyte



	Roundtable 5 Session Reserved for Event Sponsor
4:30	Chairman's closing remarks

END OF DAY TWO

